Your browser doesn't support javascript.
Protective antigenic epitopes revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine.
Peng, Mian; Dou, Xiaowen; Zhang, Xiuming; Yan, Mingchen; Xiong, Dan; Jiang, Ruiwei; Ou, Tong; Tang, Aifa; Yu, Xiqiu; Zhu, Feiqi; Li, Weiqin.
  • Peng M; The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.
  • Dou X; Department of Critical Care Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
  • Zhang X; Department of Critical Care Medicine, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
  • Yan M; Medical Laboratory, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
  • Xiong D; Medical Laboratory, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
  • Jiang R; Department of Artificial Intelligence and Bioinformatics, Shenzhen Digital Life Research Institute, Shenzhen, China.
  • Ou T; Medical Laboratory, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
  • Tang A; Medical Laboratory, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
  • Yu X; Medical Laboratory, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
  • Zhu F; Science and Education Center, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
  • Li W; Department of Gastroenterology, The Third Affiliated Hospital of Shenzhen University, Shenzhen, China.
Front Immunol ; 13: 938378, 2022.
Article in English | MEDLINE | ID: covidwho-2141954
ABSTRACT

Background:

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has infected millions of people around the world. Vaccination is a pillar in the strategy to control transmission of the SARS-CoV-2 spread. Immune responses to vaccination require elucidation.

Methods:

The immune responses to vaccination with three doses of inactivated SARS-CoV-2 vaccine were followed in a cohort of 37 healthy adults (18-59 years old). Blood samples were collected at multiple time points and submitted to peptide array, machine learning modeling, and sequence alignment analyses, the results of which were used to generate vaccine-induced antibody-binding region (VIABR) immunosignatures (Registration number ChiCTR2200058571).

Results:

Antibody spectrum signals showed vaccination stimulated antibody production. Sequence alignment analyses revealed that a third vaccine dose generated a new highly represented VIABR near the A570D mutation, and the whole process of inoculation enhanced the VIABR near the N501Y mutation. In addition, the antigen conformational epitopes varied between short- and long-term samples. The amino acids with the highest scores in the short-term samples were distributed primarily in the receptor binding domain (RBD) and N-terminal domain regions of spike (S) protein, while in the long-term samples (12 weeks after the 2nd dose), some new conformational epitopes (CEs) were localized to crevices within the head of the S protein trimer.

Conclusion:

Protective antigenic epitopes were revealed by immunosignatures after three doses of inactivated SARS-CoV-2 vaccine inoculation. A third dose results in a new top-10 VIABR near the A570D mutation site of S protein, and the whole process of inoculation enhanced the VIABR near the N501Y mutation, thus potentially providing protection from strains that have gained invasion and immune escape abilities through these mutation.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Humans / Middle aged / Young adult Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.938378

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Adolescent / Adult / Humans / Middle aged / Young adult Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.938378